Cyclacel Pharmaceuticals (CYCCP) 8.96 $CYCCP
Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments
GlobeNewswire - Mon May 05, 8:42AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been granted in the United States and other countries.
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments
GlobeNewswire - Mon May 05, 8:42AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been granted in the United States and other countries.
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. 
